H.R. 6509 — SAFE Drugs Act of 2025

Executive Summary30-second read

H.R. 6509, the Safeguarding Americans from Fraudulent and Experimental Drugs (SAFE Drugs) Act of 2025, amends the Federal Food, Drug & Cosmetic Act to tighten oversight of drug compounding and to set statutory limits on compounded drugs that are essentially copies of commercially available products. Rep. Rudy Yakym (R-IN-2) introduced it on December 9, 2025 with Democratic co-lead Rep. André Carson (D-IN-7) and 16 cosponsors. It was referred to House Energy & Commerce.

The bill raises the cap on copies of a commercially available drug a pharmacist or physician may compound to 20 per month (current FDA policy allows four), while imposing new annual reporting on physicians, facilities, and pharmacies that compound for out-of-state patients above that threshold, and subjecting large-scale outsourcing facilities to regular inspection. It is a targeted oversight measure, not a wholesale rewrite of the 2013 compounding framework.

Overview

What the bill does

• Defines a compounded drug as “essentially a copy” of a commercial product when it contains any active ingredient in that product and no patient-specific change makes it significantly different — a broader test than the FDA’s current definition, which also weighs dosage strength and route of administration.
• Raises the permitted frequency for compounding such copies to 20 times per month (current FDA policy allows four), while attaching conditions to that higher ceiling.
• Imposes annual reporting on physicians, facilities, and pharmacies (except hospital-based pharmacies) that compound copies for out-of-state patients more than 20 times a month.
• Subjects large-scale outsourcing facilities (FDA-registered 503B facilities that compound in bulk) to regular inspection and reporting requirements.
• Policy area: Health; sole referral to House Energy & Commerce. No CRS report auto-matched in the graph.

Current status

Sponsor & Cosponsors

Rep. Rudy Yakym III

Republican · IN-2 · Sponsor

House Ways & Means

Party loyalty: 98.8%

Participation: 99.4%

Victory margin: 28.1%

Threat level: Uncontested

Rep. Yakym — 119th Congress bills by status (29 sponsored)

Advancement rate 6.9% (27 of 29 bills still in committee) and an 118th-Congress Legislative Impact Index of 33.0 (low activity). Yakym sits on Ways & Means, not on Energy & Commerce — so he has no inside leverage over the committee that controls this bill.

Rep. André Carson

Democrat · IN-7 · Co-lead

Same-state Indiana cross-aisle pairing

Party loyalty: 98.8%

Participation: 97.4%

Victory margin: 39.4%

Ideology: Liberal

Caucuses: Congressional Progressive Caucus, Equality Caucus, New Democrat Coalition.

A safe-seat Democrat co-leading a Republican’s drug-safety bill gives the introduction a credible bipartisan signal — the kind of cross-aisle pairing that survives conference when provisions ride a larger vehicle.

Committee gatekeepers — House Energy & Commerce

Full cosponsor roster

Legislative Lineage9 prior bills

Drug-safety and compounding-oversight bills have been introduced repeatedly since the 117th Congress. The closest semantic cousin is S. 3794 — a same-named SAFE Drugs Act of 2026 from Sen. Jim Banks (R-IN), at 0.88 similarity — which functions as a de facto Senate companion. The pattern across the whole cluster is uniform: every bill was referred to committee, and every one died there.

Prior art — semantically similar bills

What the pattern tells us

• The policy idea is bipartisan and recurring — sponsored by Republicans and Democrats, in both chambers, across three Congresses.
• It is also institutionally stuck. Without a forcing mechanism (a must-pass attachment, an FDA user-fee reauthorization, or an unusual leadership ally), compounding-oversight bills do not advance.
• A Senate companion already exists in S. 3794 — so the two-chamber scaffolding that conference attachment requires is partly in place.

Stakeholders & MoneyForward-looking

No LDA filing yet names H.R. 6509 — normal for a bill this new, since disclosures lag about a quarter and most registrants never cite a bill number. The organizations below are inferred from who lobbied semantically similar bills. Treat them as a watchlist, not a confirmed roster.

Predicted stakeholders — full table

Issue-matched stakeholders — who actually lobbies this topic

A stronger, direct-evidence cut: rather than inferring a coalition from similar bills, this filters the lobbying record for entities whose own disclosed issues name drug compounding, 503B outsourcing facilities, or the Drug Quality & Security Act. The matches are subject-level, not bill-number-level — but they identify the players already working this exact space. The list spans both sides of the bill: the approved-product makers whose drugs compounded copies compete with (purple), and the compounding-pharmacy and 503B-outsourcing industry the bill would directly regulate (amber).

Follow the money — health-sector dollars to the signers

Tracing the campaign-finance graph backward from each signer’s committee surfaces a second, concrete signal. The bill’s 17 sponsors and cosponsors have together taken roughly $811,000 in disclosed health-sector contributions — pharma manufacturers, distributors, insurers, and hospital groups — across all cycles on file. The sponsor himself sits mid-pack at ~$59K.

Passage Outlook

The scenarios overlap because the paths are not mutually exclusive — a provision can ride a reauthorization even as the standalone bill stalls. PoliStack models attachment to a must-pass Energy & Commerce health vehicle as the single most viable route.

Bipartisan bridges — Energy & Commerce Democrats to target

To make it onto a markup or into a reauthorization without being stripped, the bill needs visible Democratic support on the committee. The members below sit on Energy & Commerce or in winnable seats where a drug-safety vote is politically defensible — eight of the ten belong to the New Democrat Coalition, the same moderate bloc all three Democratic cosponsors already sit in, which makes it the most natural channel to widen Democratic support; several are also in Problem Solvers or Climate Solutions, and two (Schrier, Ruiz) are physicians.

What would meaningfully move the odds

• Cosponsorship from a sitting Energy & Commerce member — the single most reliable unlock for a markup.
• Pairing with the existing Senate companion (S. 3794) to present a two-chamber package ahead of any FDA user-fee or health-extenders vehicle.
• A signal from Chair Guthrie or the health subcommittee that the copy-limit and outsourcing-inspection provisions are markup-eligible.
• FDA or sponsor agreement to reconcile the bill’s “essentially a copy” test with the agency’s existing definition, removing the clearest drafting objection.